A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Moderate to Severe Psoriasis
Phase of Trial: Phase I
Latest Information Update: 26 Mar 2013
At a glance
- Drugs AMG 811 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- 13 Jul 2012 Planned end date changed from 1 Aug 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 13 Jul 2012 Additional location (USA) added as reported by ClinicalTrials.gov.
- 25 Jan 2012 New trial record